Hans J. Woerle

17.1k total citations · 8 hit papers
89 papers, 13.3k citations indexed

About

Hans J. Woerle is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Hans J. Woerle has authored 89 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Endocrinology, Diabetes and Metabolism, 49 papers in Surgery and 42 papers in Molecular Biology. Recurrent topics in Hans J. Woerle's work include Diabetes Treatment and Management (74 papers), Pancreatic function and diabetes (43 papers) and Metabolism, Diabetes, and Cancer (40 papers). Hans J. Woerle is often cited by papers focused on Diabetes Treatment and Management (74 papers), Pancreatic function and diabetes (43 papers) and Metabolism, Diabetes, and Cancer (40 papers). Hans J. Woerle collaborates with scholars based in Germany, United States and United Kingdom. Hans J. Woerle's co-authors include Uli C. Broedl, Odd Erik Johansen, Maximilian von Eynatten, Michaela Mattheus, Christoph Wanner, Bernard Zinman, Silvio E. Inzucchi, John M. Lachin, John E. Gerich and David Fitchett and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Hans J. Woerle

89 papers receiving 12.9k citations

Hit Papers

Empagliflozin and Progression of Kidney Disease in Type 2... 2013 2026 2017 2021 2016 2013 2018 2014 2015 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
    2016 2.6k citations Christoph Wanner, Silvio E. Inzucchi et al. New England Journal of Medicine profile →
  2. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
    2013 976 citations David Z.I. Cherney, Bruce A. Perkins et al. Circulation profile →
  3. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
    2018 756 citations Julio Rosenstock, Odd Erik Johansen et al. profile →
  4. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
    2014 479 citations Anthony Barnett, Russell Jones et al. profile →
  5. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
    2015 372 citations Robert Ćhilton, Hans J. Woerle et al. Diabetes Obesity and Metabolism profile →
  6. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
    2017 340 citations Christoph Wanner, John M. Lachin et al. Circulation profile →
  7. Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    2014 315 citations Ludwig Merker, Thomas Meinicke et al. Diabetes Care profile →
  8. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
    2014 292 citations Julio Rosenstock, Ante Jelaska et al. Diabetes Care profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hans J. Woerle Germany 49 11.4k 5.5k 5.1k 1.8k 1.6k 89 13.3k
Odd Erik Johansen United States 35 14.8k 1.3× 6.3k 1.1× 5.8k 1.1× 2.1k 1.2× 1.8k 1.1× 123 17.8k
Avivit Cahn Israel 29 7.7k 0.7× 3.0k 0.5× 3.1k 0.6× 824 0.5× 839 0.5× 113 9.3k
Guntram Schernthaner Austria 60 6.2k 0.5× 2.7k 0.5× 2.9k 0.6× 1.0k 0.6× 924 0.6× 227 11.0k
Uli C. Broedl Germany 55 18.6k 1.6× 9.2k 1.7× 8.3k 1.6× 2.5k 1.4× 2.6k 1.7× 118 23.1k
B Charbonnel France 46 7.1k 0.6× 2.8k 0.5× 3.3k 0.6× 470 0.3× 1.1k 0.7× 240 9.7k
Gary Meininger United States 40 7.3k 0.6× 3.8k 0.7× 3.0k 0.6× 639 0.4× 1.4k 0.9× 80 8.3k
Steven P. Marso United States 31 9.0k 0.8× 3.2k 0.6× 3.4k 0.7× 451 0.3× 1.9k 1.2× 74 11.2k
James F. List United States 32 6.7k 0.6× 3.3k 0.6× 3.5k 0.7× 666 0.4× 1.3k 0.8× 46 7.3k
Giancarlo Viberti United Kingdom 62 6.6k 0.6× 2.1k 0.4× 3.7k 0.7× 4.0k 2.2× 970 0.6× 190 13.7k
Avraham Karasik Israel 41 5.5k 0.5× 2.2k 0.4× 4.0k 0.8× 429 0.2× 867 0.5× 126 10.8k

Countries citing papers authored by Hans J. Woerle

Since Specialization
Citations

This map shows the geographic impact of Hans J. Woerle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans J. Woerle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans J. Woerle more than expected).

Fields of papers citing papers by Hans J. Woerle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans J. Woerle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans J. Woerle. The network helps show where Hans J. Woerle may publish in the future.

Co-authorship network of co-authors of Hans J. Woerle

This figure shows the co-authorship network connecting the top 25 collaborators of Hans J. Woerle. A scholar is included among the top collaborators of Hans J. Woerle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans J. Woerle. Hans J. Woerle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Coleman, Ruth L., Alastair Gray, Uli C. Broedl, et al.. (2020). Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. Diabetes Obesity and Metabolism. 22(7). 1151–1156. 12 indexed citations
2.
Wanner, Christoph, John M. Lachin, Silvio E. Inzucchi, et al.. (2017). Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 137(2). 119–129. 340 indexed citations breakdown →
3.
Wanner, Christoph, Silvio E. Inzucchi, John M. Lachin, et al.. (2016). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 375(4). 323–334. 2583 indexed citations breakdown →
4.
Ćhilton, Robert, Lars Gullestad, Silvio E. Inzucchi, et al.. (2016). Abstract 13520: Empagliflozin Reduces Markers of Arterial Stiffness, Vascular Resistance and Cardiac Workload in EMPA-REG OUTCOME. Circulation. 134(suppl_1). 9 indexed citations
5.
Roden, Michael, Ludwig Merker, Anita Vedel Christiansen, et al.. (2015). Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovascular Diabetology. 14(1). 154–154. 101 indexed citations
6.
7.
8.
Rosenstock, Julio, Ante Jelaska, Guillaume Frappin, et al.. (2014). Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care. 37(7). 1815–1823. 292 indexed citations breakdown →
9.
Cherney, David Z.I., Bruce A. Perkins, Nima Soleymanlou, et al.. (2013). Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus. Circulation. 129(5). 587–597. 976 indexed citations breakdown →
10.
Seman, Leo, Sreeraj Macha, Gerhard Nehmiz, et al.. (2013). Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects. Clinical Pharmacology in Drug Development. 2(2). 152–161. 111 indexed citations
11.
Kanada, Shigeto, Kazuki Koiwai, Atsushi Taniguchi, et al.. (2013). Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 4(6). 613–617. 41 indexed citations
12.
Haak, T, et al.. (2013). Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double‐blind 1‐year extension study. International Journal of Clinical Practice. 67(12). 1283–1293. 28 indexed citations
13.
14.
Sarashina, Akiko, Kazuki Koiwai, Leo Seman, et al.. (2012). Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects. Drug Metabolism and Pharmacokinetics. 28(3). 213–219. 73 indexed citations
15.
16.
Prato, Stefano Del, Anthony Barnett, Holger Huisman, et al.. (2010). Effect of linagliptin monotherapy on glycaemic control and markers of β ‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obesity and Metabolism. 13(3). 258–267. 259 indexed citations
17.
Schirra, Jörg, et al.. (2009). GLP‐1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterology & Motility. 21(6). 609–609. 67 indexed citations
18.
Woerle, Hans J., Rainer Linke, Christoph Neumann, et al.. (2008). Impaired Hyperglycemia-Induced Delay in Gastric Emptying in Patients With Type 1 Diabetes Deficient for Islet Amyloid Polypeptide. Diabetes Care. 31(12). 2325–2331. 47 indexed citations
19.
Woerle, Hans J., et al.. (2007). Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Diabetes Research and Clinical Practice. 77(2). 280–285. 252 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Odd Erik Johansen Breakdown of academic impact, for papers by Avivit Cahn Breakdown of academic impact, for papers by Guntram Schernthaner Breakdown of academic impact, for papers by Uli C. Broedl Breakdown of academic impact, for papers by B Charbonnel Breakdown of academic impact, for papers by Gary Meininger Breakdown of academic impact, for papers by Steven P. Marso Breakdown of academic impact, for papers by James F. List Breakdown of academic impact, for papers by Giancarlo Viberti Breakdown of academic impact, for papers by Avraham Karasik
Rankless by CCL
2026